Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer*S⃞

Tamoxifen resistance is a major cause of death in patients with recurrent breast cancer. Current clinical factors can correctly predict therapy response in only half of the treated patients. Identification of proteins that are associated with tamoxifen resistance is a first step toward better response prediction and tailored treatment of patients. In the present study we intended to identify putative protein biomarkers indicative of tamoxifen therapy resistance in breast cancer using nano-LC coupled with FTICR MS. Comparative proteome analysis was performed on ∼5,500 pooled tumor cells (corresponding to ∼550 ng of protein lysate/analysis) obtained through laser capture microdissection (LCM) from two independently processed data sets (n = 24 and n = 27) containing both tamoxifen therapy-sensitive and therapy-resistant tumors. Peptides and proteins were identified by matching mass and elution time of newly acquired LC-MS features to information in previously generated accurate mass and time tag reference databases. A total of 17,263 unique peptides were identified that corresponded to 2,556 non-redundant proteins identified with ≥2 peptides. 1,713 overlapping proteins between the two data sets were used for further analysis. Comparative proteome analysis revealed 100 putatively differentially abundant proteins between tamoxifen-sensitive and tamoxifen-resistant tumors. The presence and relative abundance for 47 differentially abundant proteins were verified by targeted nano-LC-MS/MS in a selection of unpooled, non-microdissected discovery set tumor tissue extracts. ENPP1, EIF3E, and GNB4 were significantly associated with progression-free survival upon tamoxifen treatment for recurrent disease. Differential abundance of our top discriminating protein, extracellular matrix metalloproteinase inducer, was validated by tissue microarray in an independent patient cohort (n = 156). Extracellular matrix metalloproteinase inducer levels were higher in therapy-resistant tumors and significantly associated with an earlier tumor progression following first line tamoxifen treatment (hazard ratio, 1.87; 95% confidence interval, 1.25–2.80; p = 0.002). In summary, comparative proteomics performed on laser capture microdissection-derived breast tumor cells using nano-LC-FTICR MS technology revealed a set of putative biomarkers associated with tamoxifen therapy resistance in recurrent breast cancer.

[1]  E. Bieberich,et al.  Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide , 2008, Breast Cancer Research.

[2]  S. Franceschi,et al.  Effect of obesity and other lifestyle factors on mortality in women with breast cancer , 2008, International journal of cancer.

[3]  M. Flechtner-Mors,et al.  Association of Genetic Variation in ENPP1 With Obesity‐related Phenotypes , 2008, Obesity.

[4]  Yasuhiro Ito,et al.  S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. , 2008, Current cancer drug targets.

[5]  M. Georgescu.  NHERF1: molecular brake on the PI3K pathway in breast cancer , 2008, Breast Cancer Research.

[6]  Baogang J. Xu,et al.  Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. , 2008, Journal of proteome research.

[7]  Navdeep Jaitly,et al.  DeconMSn: a software tool for accurate parent ion monoisotopic mass determination for tandem mass spectra , 2008, Bioinform..

[8]  J. Jones,et al.  A review of the S100 proteins in cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  Navdeep Jaitly,et al.  VIPER: an advanced software package to support high-throughput LC-MS peptide identification , 2007, Bioinform..

[10]  Torben F. Ørntoft,et al.  Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer , 2007, Clinical Cancer Research.

[11]  M. Osanai,et al.  Occludin‐mediated premature senescence is a fail‐safe mechanism against tumorigenesis in breast carcinoma cells , 2007, Cancer science.

[12]  Richard D. Smith,et al.  Targeted tandem mass spectrometry for high-throughput comparative proteomics employing NanoLC-FTICR MS with external ion dissociation , 2007, Journal of the American Society for Mass Spectrometry.

[13]  T. Luider,et al.  Identification of Glioma Neovascularization-related Proteins by Using MALDI-FTMS and Nano-LC Fractionation to Microdissected Tumor Vessels* , 2007, Molecular & Cellular Proteomics.

[14]  S. De Cosmo,et al.  ENPP1 gene, insulin resistance and related clinical outcomes , 2007, Current opinion in clinical nutrition and metabolic care.

[15]  R. Layfield,et al.  Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. , 2007, International journal of oncology.

[16]  F. Shibasaki,et al.  Mammalian Tumor Suppressor Int6 Specifically Targets Hypoxia Inducible Factor 2α for Degradation by Hypoxia- and pVHL-independent Regulation* , 2007, Journal of Biological Chemistry.

[17]  I. Mazo,et al.  Expression of EIF3-p48/INT6, TID1 and Patched in cancer, a profiling of multiple tumor types and correlation of expression. , 2007, Journal of biomedical science.

[18]  J. Foekens,et al.  NanoLC‐FT‐ICR MS improves proteome coverage attainable for ∼3000 laser‐microdissected breast carcinoma cells , 2007, Proteomics.

[19]  P. Drew,et al.  The proteomic analysis of cisplatin resistance in breast cancer cells. , 2007, Oncology research.

[20]  J. Foekens,et al.  NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells. , 2007, Proteomics.

[21]  C. Lebbé,et al.  Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. , 2007, Cancer research.

[22]  R. Callahan,et al.  Expression of truncated Int6/eIF3e in mammary alveolar epithelium leads to persistent hyperplasia and tumorigenesis , 2007, Breast Cancer Research.

[23]  R. Schiff,et al.  Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. , 2006, Endocrine-related cancer.

[24]  Ronald J Moore,et al.  Chemically etched open tubular and monolithic emitters for nanoelectrospray ionization mass spectrometry. , 2006, Analytical chemistry.

[25]  A. Borowsky,et al.  Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer , 2006, Proceedings of the National Academy of Sciences.

[26]  A. Chambery,et al.  Proteomic analysis of MCF‐7 breast cancer cell line exposed to mitogenic concentration of 17β‐estradiol , 2006, Proteomics.

[27]  I. Lazar,et al.  Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation. , 2006, Rapid communications in mass spectrometry : RCM.

[28]  G. Sauter,et al.  High incidence of EMMPRIN expression in human tumors , 2006, International journal of cancer.

[29]  Richard D. Smith,et al.  Robust algorithm for alignment of liquid chromatography-mass spectrometry analyses in an accurate mass and time tag data analysis pipeline. , 2006, Analytical chemistry.

[30]  Kun Yu,et al.  Quantitative profiling of drug-associated proteomic alterations by combined 2-nitrobenzenesulfenyl chloride (NBS) isotope labeling and 2DE/MS identification. , 2006, Journal of proteome research.

[31]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[32]  Yi Zhang,et al.  Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Richard D. Smith,et al.  Quantitative proteome analysis of breast cancer cell lines using 18O‐labeling and an accurate mass and time tag strategy , 2006, Proteomics.

[34]  T. Fehm,et al.  Breast cancer proteomics by laser capture microdissection, sample pooling, 54‐cm IPG IEF, and differential iodine radioisotope detection , 2006, Electrophoresis.

[35]  J. Foekens,et al.  Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Foekens,et al.  Laser microdissection and microarray analysis of breast tumors reveal ER-α related genes and pathways , 2006, Oncogene.

[37]  E. Kubista,et al.  Proteomic analysis in human breast cancer: Identification of a characteristic protein expression profile of malignant breast epithelium , 2006, Proteomics.

[38]  M. Gerdes,et al.  CLIC4, an intracellular chloride channel protein, is a novel molecular target for cancer therapy. , 2005, The journal of investigative dermatology. Symposium proceedings.

[39]  Ronald J Moore,et al.  Development and evaluation of a micro- and nanoscale proteomic sample preparation method. , 2005, Journal of proteome research.

[40]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[41]  J. Foekens,et al.  Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix‐assisted laser desorption/ionisation‐time of flight and matrix‐assisted laser desorption/ionisation‐time of flight/time of flight‐mass spectrometry , 2005, Proteomics.

[42]  A. Emili,et al.  Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. , 2005, Journal of proteome research.

[43]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[44]  Lei Zhang,et al.  Sphingosine-1-Phosphate Lyase Regulates Sensitivity of Human Cells to Select Chemotherapy Drugs in a p38-Dependent Manner , 2005, Molecular Cancer Research.

[45]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[46]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Veldhoven,et al.  Sphingosine-1-Phosphate Lyase Regulates Sensitivity of Human Cells to Select Chemotherapy Drugs in a p 38-Dependent Manner , 2005 .

[48]  Richard D. Smith,et al.  Proteomic analyses using an accurate mass and time tag strategy. , 2004, BioTechniques.

[49]  Catherine Fenselau,et al.  Evaluation of metabolic labeling for comparative proteomics in breast cancer cells. , 2004, Journal of proteome research.

[50]  G. Sauter,et al.  Expression of Extracellular Matrix Metalloproteases Inducer on Micrometastatic and Primary Mammary Carcinoma Cells , 2004, Clinical Cancer Research.

[51]  D. Sgroi,et al.  Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling. , 2004, Journal of proteome research.

[52]  Ronald J Moore,et al.  Multidimensional proteome analysis of human mammary epithelial cells. , 2004, Journal of proteome research.

[53]  Nikola Tolić,et al.  Ultrasensitive proteomics using high-efficiency on-line micro-SPE-nanoLC-nanoESI MS and MS/MS. , 2004, Analytical chemistry.

[54]  C. Tuquet,et al.  Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria , 2004, Cell Biology and Toxicology.

[55]  Minetta C. Liu,et al.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.

[56]  W. Hancock,et al.  An approach to the proteomic analysis of a breast cancer cell line (SKBR‐3) , 2003, Proteomics.

[57]  Gordon A Anderson,et al.  Use of artificial neural networks for the accurate prediction of peptide liquid chromatography elution times in proteome analyses. , 2003, Analytical chemistry.

[58]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[59]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  B. Toole,et al.  Tumorigenic potential of extracellular matrix metalloproteinase inducer. , 2001, The American journal of pathology.

[61]  A. Marchetti,et al.  Reduced expression of INT-6/eIF3-p48 in human tumors. , 2001, International journal of oncology.

[62]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[63]  E. Petricoin,et al.  Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines , 2000, Electrophoresis.

[64]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[65]  S. Shaffer,et al.  Characterization of an improved electrodynamic ion funnel interface for electrospray ionization mass spectrometry. , 1999, Analytical chemistry.

[66]  L. Liotta,et al.  Laser Capture Microdissection , 1996, Science.

[67]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[68]  T. Terasawa.  [Assessment of response to therapy in advanced breast cancer]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

[69]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. , 1978, European journal of cancer.

[70]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.